MedTrace Logo

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

NCT02003144 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2022-08-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

Conditions

Interventions

BIOLOGICAL

eculizumab

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-12
Primary Completion
2021-07-12
Completion
2021-07-12

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Colombia
  • Croatia
  • Czechia
  • Denmark
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Malaysia
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003144 on ClinicalTrials.gov